CSIMarket Company Name, Ticker, Suppliers, else..
 
Ideaya Biosciences Inc   (IDYA)
Other Ticker:  
 
 
Price: $30.4700 $-0.43 -1.392%
Day's High: $31.075 Week Perf: -1.9 %
Day's Low: $ 30.37 30 Day Perf: -18.66 %
Volume (M): 475 52 Wk High: $ 47.74
Volume (M$): $ 14,461 52 Wk Avg: $37.67
Open: $30.79 52 Wk Low: $23.41



 Market Capitalization (Millions $) 1,828
 Shares Outstanding (Millions) 60
 Employees -
 Revenues (TTM) (Millions $) 23
 Net Income (TTM) (Millions $) -103
 Cash Flow (TTM) (Millions $) 51
 Capital Exp. (TTM) (Millions $) 2

Ideaya Biosciences Inc
Ideaya Biosciences Inc is a clinical-stage biotechnology company that focuses on the discovery and development of targeted therapeutics for patients with genomically defined cancers. The company utilizes its proprietary Synthetic Lethality Platform to identify and develop small molecules that can selectively target specific cancer-causing genetic alterations. By targeting these alterations, Ideaya aims to develop precise and effective treatments that can improve patient outcomes. The company is engaged in multiple clinical programs and collaborations with leading academic and pharmaceutical partners to advance its innovative pipeline of therapies.


   Company Address: 7000 Shoreline Court South San Francisco 94080 CA
   Company Phone Number: 443-6209   Stock Exchange / Ticker: NASDAQ IDYA


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
• View Complete Report
   



Business Update

IDEAYA Biosciences Develops Targeted B7H3/PTK7 Antibody-Drug Conjugate for Cancer Treatment

Published Thu, Aug 1 2024 6:28 AM UTC

IDEAYA Biosciences Advances Cancer Therapeutics with B7H3/PTK7-ADCIDEAYA Biosciences, Inc. (Nasdaq: IDYA) is making significant strides in the field of cancer therapeutics with its latest development of the B7H3/PTK7 antibody-drug conjugate (ADC), identified as ADC02315. This progressive approach leverages targeted therapy mechanisms to improve treatment outcomes for patien...
Business Update

Biocytogen and IDEAYA Biosciences Forge Partnership to Develop Pioneering B7H3/PTK7 Bispecific Antibody-Drug Conjug...

Published Wed, Jul 31 2024 10:47 AM UTC

In a significant move that promises to advance the field of targeted cancer therapies, Biocytogen Pharmaceuticals (Beijing) Co., Ltd., recently announced an option and license agreement with IDEAYA Biosciences, Inc. This agreement centers around a groundbreaking bispecific antibody-drug conjugate (BsADC) program targeting B7H3 and PTK7, a combination that could set the stage...
Personnel Announcements

IDEAYA Biosciences Appoints Daniel A. Simon as Chief Business Officer to Steer Corporate Strategy and Overcome Financial Challenges.

Published Tue, May 28 2024 10:00 AM UTC

IDEAYA Biosciences Appoints Daniel A. Simon as Chief Business Officer to Lead Corporate Strategy and Business Development
IDEAYA Biosciences, a precision medicine company specializing in oncology, has recently announced the appointment of Daniel A. Simon as the new Chief Business Officer. Simon brings with him extensive experience in the life sciences industry and strat...
Ideaya Biosciences Inc

Ideaya Biosciences Inc's Q3 2023 Earnings Season Indicates a Harsh Blow to Financial Progress



Ideaya Biosciences Inc, a biotechnology company, recently announced its Sep 30, 2023 report, which came as a disappointment to investors and industry analysts. The report highlighted a significant decline in revenue and widening shortfall per share compared to the prior reporting season. In this article, we delve deeper into these facts and shed light on the financial performance of Ideaya Biosciences Inc.
Revenue Plunge and Widening Shortfall
The most concerning aspect of Ideaya Biosciences Inc's Sep 2023 report is the sharp decline in revenue. Compared to the previous year's reporting season, revenue faded by a staggering -72.935% to $8.04 million. This substantial decline in revenue showcases the challenges faced by the company during this period.
Ideaya Biosciences Inc

Ideaya Biosciences Inc's Financial Crisis: Revenue Plummets by -39.429% and Net Deficit of $-0.50 per Share in Q2 2023 Raises Concerns for Investors


Introduction
In the second quarter of 2023, Ideaya Biosciences Inc, a major pharmaceutical preparations company, reported disheartening financial results that caught the attention of investors. With a significant drop in revenue and an increased net deficit per share, the company's performance has raised concerns about its current financial standing and future growth prospects.
Plummeting Revenue and Net Deficit
During the second quarter of 2023, Ideaya Biosciences Inc witnessed a dramatic decline in revenue, which melted down by a staggering -39.429% to $3.54 million, compared to the previous reporting season. Such a massive drop in revenue signals a potential decline in demand for the company's products, raising questions about their competitiveness in the pharmaceutical market.






Ideaya Biosciences Inc's Segments





Help

About us

Advertise
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com